Thrombophilia classification

Revision as of 15:27, 19 July 2016 by Anthony Gallo (talk | contribs)
Jump to navigation Jump to search

Thrombophilia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombophilia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombophilia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombophilia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombophilia classification

CDC on Thrombophilia classification

Thrombophilia classification in the news

Blogs on Thrombophilia classification

Directions to Hospitals Treating Thrombophilia

Risk calculators and risk factors for Thrombophilia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2]

Overview

Thrombophilia may be classified into three subtypes: inherited or primary hypercoagulable states, acquired or secondary hypercoagulable states, and mixed/unknown.[1][2]

Classification

  • Thrombophilia may be classified into three subtypes:[1][2]
  • Inherited thrombophilia or primary hypercoagulable state
  • Acquired thrombophilia or secondary hypercoagulable state
  • Mixed/Unknown
  • Different thrombophilic states are associated with venous or both venous and arterial clots.
Thrombophilia Classification
Inherited (Primary) Acquired (Secondary) Mixed/Unknown
Activated protein C resistance (Factor V Leiden) Age Hyperhomocysteinemia
Prothrombin gene mutation (Prothrombin G20210A) Immobilization APC resistance unrelated to Factor V Leiden.
Antithrombin deficiency Trauma/major surgery Increased Factor VIII levels
Protein C and Protein S deficiency Orthopedic surgery Increased Factor XI levels
Dysfibrinogenemia Malignancy Increased ]]Factor IX]] levels
Non-O blood type Myeloproliferative disorders (polycythemia vera, essential thrombocythemia, hyperviscosity) Increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI)
Pregnancy Decreased levels of free tissue factor pathway inhibitor (TFPI)
Estrogen and testosterone (oral contraceptives, hormone replacement therapy, and selective estrogen receptor modulator)
Obesity
Heart Failure
Cirrhosis
Chronic renal disease, Nephrotic syndrome
Antiphospholipid syndrome (APLS) or lupus anticoagulant
Heparin-induced thrombocytopenia (HIT)
Disseminated intravascular coagulopathy (DIC)
Paroxysmal nocturnal hemoglobinuria (PNH)
Autoimmune disorders (Vasculitis, Celiac disease, Inflammatory bowel disease)
Thrombotic microangiopathy
Sickle cell disease
Drug related (chemotherapies including L-aspariginase, mitomycin; infusion of clotting factors including prothrombin complex concentrates, cryoprecipitate; drugs including hydralazine, procainamide, or phenothiazines can promote lupus anticoagulant formation)
Thrombophilic states associated with arterial clots
APLS and lupus anticoagulant
HIT
DIC
PNH
Cold agglutinins (associated with mycoplasma infections)
Vasculitis
Hyperhomocysteinemia

References

  1. 1.0 1.1 Hoffman R, Benz EJ, Shattil SJ, et al. Hematology: Basic Principles and Practice: Elsevier Science Health Science Division; 2004.
  2. 2.0 2.1 Cohoon KP, Heit JA (2014). "Inherited and secondary thrombophilia". Circulation. 129 (2): 254–7. doi:10.1161/CIRCULATIONAHA.113.001943. PMC 3979345. PMID 24421360.

Template:WH Template:WS